16-OCT-07

RESEARCH TRIANGLE PARK, NC, October 16, 2007 -- CeNeRx BioPharma, Inc., a biopharmaceutical
company developing and commercializing innovative treatments for diseases of the central nervous
system, today announced the addition of Daniel Burch, M.D., M.B.A. as Executive Vice President of
R&D and Chief Medical Officer. Dr. Burch will play a critical role in building and advancing the
CeNeRx product portfolio and leading its research and development programs.

“We are delighted to have Dan join the CeNeRx team,” said Barry Brand, CEO of CeNeRx BioPharma.
“We expect his expertise and proven track record of leadership in bringing significant drugs to the
market will contribute greatly to our mission of developing important new CNS medicines for
underserved conditions. His deep knowledge of the global regulatory process and successful
partnering experience should be very valuable to CeNeRx as we advance our current product
candidates and potentially expand our pipeline programs.”

Dr. Burch’s broad industry experience includes 15 years of developing new medicines at Abbott
Laboratories, SmithKline Beecham and GlaxoSmithKline (GSK). His most recent post at GSK was
Senior Vice President and Head of the Neurosciences Medicine Development Centre, where he was
responsible for building and managing the global neuroscience drug development portfolio and was
accountable for delivering important CNS products addressing depression, movement disorders, pain
and Alzheimer’s disease. In his pharmaceutical industry career, Dr. Burch has worked to establish
new business ventures and has held leadership positions in a variety of therapeutic areas and
functions.

"CeNeRx is an exciting opportunity with a pipeline of novel potential medicines addressing areas of
high unmet need,” said Dr. Burch. “I look forward to working with the CeNeRx team to advance the
company’s lead RIMA series, which appears to hold great promise as an important addition to the
management of major depressive disorder, as well as its selective cannabinoid program with
significant potential in pain, obesity and other CNS-related conditions.”

Dr. Burch received a B.S. degree from the University of South Carolina, an M.D. degree from the
Vanderbilt University School of Medicine and an M.B.A. degree from the Wharton School at the
University of Pennsylvania. He is co-author of numerous scientific papers and is the inventor on
several patents. Among other professional activities, Dr. Burch has served on the National Institute
on Medicine's Forum on Neurosciences and Nervous System Disorders.

About CeNeRx BioPharma
CeNeRx (SEN-er-ex) is a privately held clinical stage biopharmaceutical company developing and
commercializing innovative treatments for diseases of the central nervous system. CeNeRx’s most
advanced compounds, reversible inhibitors of monoamine oxidase, or RIMAs, are in late preclinical
and Phase I development for the treatment of major depressive disorder. RIMAs may have efficacy
advantages over current agents for depression and are expected to have a good safety profile. The
company is also developing its preclinical pipeline of selective cannabinoid compounds for the
treatment of pain, glaucoma and obesity. More information about CeNeRx BioPharma can be found
at www.cenerx.com.